Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The input 'JAK2, SRC, FAK' refers to a grouping of three distinct, well-defined non-receptor tyrosine kinases: Janus kinase 2 (JAK2), Proto-oncogene tyrosine-protein kinase Src (SRC), and Focal adhesion kinase 1 (FAK). Each is an independent therapeutic target involved in critical cellular processes such as signal transduction, proliferation, adhesion, migration, and immune response. While distinct, they often participate in interconnected signaling pathways. This annotation aggregates information pertinent to all three given the query format, though detailed mechanisms and specific roles vary for each individual kinase.
These targets are distinct non-receptor tyrosine kinases whose individual inhibition impacts diverse cellular processes including proliferation, survival, adhesion, migration, and immune signaling, often relevant in cancer and inflammatory diseases. Specific mechanisms of action vary per kinase.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JAK2, SRC, FAK.